8PT9 image
Entry Detail
PDB ID:
8PT9
Title:
JNK1 covalently bound to BD838 cyclohexenone based inhibitor
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2023-07-13
Release Date:
2024-07-24
Method Details:
Experimental Method:
Resolution:
2.70 Å
R-Value Free:
0.22
R-Value Work:
0.20
R-Value Observed:
0.21
Space Group:
P 31
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Mitogen-activated protein kinase 8
Chain IDs:A, B, C
Chain Length:366
Number of Molecules:3
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Reversible covalent c-Jun N-terminal kinase inhibitors targeting a specific cysteine by precision-guided Michael-acceptor warheads.
Nat Commun 15 8606 8606 (2024)
PMID: 39366946 DOI: 10.1038/s41467-024-52573-2

Abstact

There has been a surge of interest in covalent inhibitors for protein kinases in recent years. Despite success in oncology, the off-target reactivity of these molecules is still hampering the use of covalent warhead-based strategies. Herein, we disclose the development of precision-guided warheads to mitigate the off-target challenge. These reversible warheads have a complex and cyclic structure with optional chirality center and tailored steric and electronic properties. To validate our proof-of-concept, we modified acrylamide-based covalent inhibitors of c-Jun N-terminal kinases (JNKs). We show that the cyclic warheads have high resilience against off-target thiols. Additionally, the binding affinity, residence time, and even JNK isoform specificity can be fine-tuned by adjusting the substitution pattern or using divergent and orthogonal synthetic elaboration of the warhead. Taken together, the cyclic warheads presented in this study will be a useful tool for medicinal chemists for the deliberate design of safer and functionally fine-tuned covalent inhibitors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures